At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 50 enrolled
Drug / intervention
DynamX Novolimus Eluting Coronary Bioadaptor Systemcombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Non-Randomized, Clinical Registry of the Dynamx Novolimus Eluting Coronary Bioadaptor System in the Treatment of Patients With De Novo Native Coronary Artery Lesions
In Brief
A Phase 4 clinical trial evaluating DynamX Novolimus Eluting Coronary Bioadaptor System for Coronary Artery Disease. Completed, enrolled 50 participants across 4 sites.
Detailed Summary
Prospective, non-randomized, multicenter registry
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartSep 2020
Primary CompletionDec 2022
TodayJul 2026
First PostedJul 23, 2020
Enrollment StartSep 30, 2020
Primary CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.9 years ago
Interventions
DynamX Novolimus Eluting Coronary Bioadaptor Systemcombination
up to two de novo native coronary artery lesions measuring between 2.25 and 3.5 mm in diameter and\<=34 mm in length receiving the DynamX Novolimus Eluting Coronary Bioadaptor System